Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 1997

View Archived Issues

Enzon: fiscal 1997 highlights

Algene: Q2 1997 highlights

Safety profile of VRCTC-310 established in rabbits

Boston Life Sciences reports phase III results for Therafectin

Favorable phase II/III data for Targretin in CTCL reported at dermatology congress

Cytel reports encouraging results from Cylexin phase I/II trial

Dyax issued U.S. patent for novel elastase inhibitors

Genetronics receives NCI grant for electroporation research

Quinacrine sterilization reviewed

Efficacy of Viramune triple drug combination reported at ICAAC

Byk Gulden presents new gastric antisecretory agents

Schering AG prepares new rolipram derivatives

Focus on benzoyl guanidines as Na+/H+-exchange inhibitors

Optically active analgesic agent presented by Roche

New polyene antifungal antibiotic developed at Ajinomoto

BioChem Therapeutic discovers new anti-HCMV agents

Development of YM-46303 stopped

North American Vaccine advances with meningitis B vaccine

Dexketoprofen trometamol submitted for mutual EC recognition

Phase II results reported for Neurobloc

Nyotran study results described at ICAAC

Wakunaga develops new oral fluoroquinolones

T-3811: a new des-F(6)-quinolone from Toyama presented at ICAAC

SynPhar selects class C beta-lactamase inhibitor as development candidate

Cor Therapeutics submits NDA amendment for Integrilin to FDA

First registration filing for Unigene's injectable calcitonin product

Five efavirenz studies reported at ICAAC

Triazole antifungal from Uriach heading for clinic

Fortovase compares favorably with Crixivan and Invirase

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...